Novartis to buy breast cancer drug candidate from Synnovation
Novartis is set to acquire a promising breast cancer drug candidate from Synnovation Therapeutics in a deal worth up to $3 billion, strengthening its oncology pipeline. The experimental therapy targets HR-positive/HER2-negative breast cancer using a next-generation PI3Kα inhibition approach.
Ludwig Burger/Reuters
March 20, 2026
FILE PHOTO: The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020.
Arnd Wiegmann/Reuters
Novartis NOVN.S said on Friday it agreed to acquire breast cancer drug candidate SNV4818 from Synnovation Therapeutics for $2 billion upfront and up to $1 billion contingent on further development achievements.
The experimental drug belongs to the class of selective PI3Kα inhibitors, a new approach for the treatment of a type of breast cancer known as HR positive/HER2 negative and potentially other solid tumours.
-Ludwig Burger/Reuters
TOP HEALTH STORIES
UNICEF: 1.9 million malnourished Somali children expected this year as aid cuts worsen hunger crisis
ANALYSIS: Why salmonella causes severe illness in some people but not others
WHO: Ebola outbreak in Congo can be controlled within three months
LATEST NEWS
PH gov't sets aside P1 billion for AI-powered flood forecasting
Bus carrying German high school students crashes in Netherlands
Indonesia says August 15 earthquake death toll reaches 100
Paraluman News Publication, Inc.
desk@myparaluman.ph
Tektite Towers (East), Exchange Road
Ortigas Center. San Antonio 1600
City of Pasig, NCR, Philippines
+63284298877
EXPLORE
Editorial Standards and Code of Ethics
Privacy Policy
User Policy
COMMUNITY
Contributor and Campus Voices Terms
Advertise with Paraluman News
ACCOUNTABILITY & SAFETY
Submit a Claim for Fact-Checking
© 2026 Paraluman News Publication